Besides in vitro and in vivo PRRSV infection, to further investigate in vivo effects of pGM-CSF on PRRSV infection processes, we retested serum and PAMs samples obtained from our previous animal study investigating therapeutic potential of a broad-spectrum neutralizing monoclonal antibody against in vivo infection cause by heterogeneous PRRSV strains (38). The gene discussed is CSF1; the disease is infection.